Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, acute lymphocytic (ALL), child
Stage/Subtype:  recurrent childhood acute lymphoblastic leukemia
Trial Type:  Treatment
Results 1-25 of 63 for your search:
Start Over
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: SHP620-303, NCI-2016-01720, 2015-004725-13, NCT02931539
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Not yet active
Phase: Phase III
Type: Prevention, Supportive care, Treatment
Age: 2 to 25
Trial IDs: ACCL1633, NCI-2017-00208, COG-ACCL1633, NCT03057054
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Fludarabine Phosphate, Busulfan, Anti-thymocyte Globulin, and Total-Body Irradiation before Donor Stem Cell Transplant in Treating Younger Patients with Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: SCT 0208, NCI-2015-00140, CMH SCT 0208, NCT00679536
Multi-Virus-Specific Donor T Cells in Treating Patients With B Cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 80 and under
Trial IDs: MULTIPRAT, NCI-2012-00636, H-23637, NCT00840853
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NCT01203722
Conventional and Regulatory T Cells in Treating Patients with Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, NCT02053545
CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Talazoparib and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1411, NCI-2014-00804, NCT02116777
DT2219 Immunotoxin in Treating Patients with Relapsed or Refractory CD19 Positive or CD22 Positive B-Cell Leukemia or Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2014LS093, NCI-2015-00555, HM2014-26, NCT02370160
Pexidartinib in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 10 and over
Trial IDs: 2014-0521, NCI-2015-00779, NCT02420717
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 2 and over
Trial IDs: 14548, NCI-2015-01512, 2014-005024-10, I6F-MC-JJCB, NCT02518113
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients with Hematologic Malignancies Undergoing HSCT
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 3 to 30
Trial IDs: PEDSBMT295, NCI-2016-00387, NCT02728700
Neratinib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors or Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 21
Trial IDs: 16-878, NCI-2016-01571, NCT02932280
Inotuzumab Ozogamicin in Treating Patients with Acute Lymphocytic Leukemia after Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 to 75
Trial IDs: CASE1916, NCI-2017-00826, NCT03104491
Donor Stem Cell Transplant in Treating Patients With Hematological Malignancies Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 25 and under
Trial IDs: MOHEL, NCI-2012-00807, H-8701, NCT00368355
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 65
Trial IDs: 2275.00, NCI-2010-00299, 2275, FHCRC-2275.00, IR-6800, NCT00796068
Start Over